OncXerna Therapeutics Provides New Results from its Xerna™ RNA-based Biomarker Platform at the AACR Annual Meeting
Xerna™ TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities…
Xerna™ TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities…
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical…
LONDON, April 10, 2021 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical…
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP),…
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in…
~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a…
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused…
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer…
Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ Cells…
CAMBRIDGE, Mass. and NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….